title: Genetic screening for neovascular AMD: cost effective…not so quick.
abstract: The following is a response to Brown and colleagues (Int J Retin Vitr 1:19, 2015), who analyzed the cost effectiveness of genetic screening for neovascular AMD in Category 3 (intermediate). As explained in this letter, it is premature to propose that genetic screening is cost effective in this setting. A simple clinical history and macular exam is highly cost effective and can easily guide screening strategies.
authors.affiliation: New England Eye Center Boston, 800 Washington St, Boston, MA 02111 USA.
authors.forename: Elias
authors.identifier: 0000-0002-5385-1103
authors.initials: E
authors.lastname: Reichel